论文部分内容阅读
目的探讨运用促性腺激素释放激素激动剂联合内美通治疗子宫内膜异位症,临床疗效与药物不良反应分析。方法将60例子宫内膜异位症患者随机分为两组:治疗组30例,给与促性腺激素释放激素激动剂联合内美通治疗;对照组30例,给与促性腺激素释放激素激动剂治疗。并对两组患者治疗后对其疗效进行对比分析及内分泌激素测定E2了解情况。结果 60例子宫内膜异位症患者治疗后,治疗组:完全缓解26例占86.7%,部分缓解2例占6.7%,复发2例占6.7%;对照组:完全缓解22例占73.3%,部分缓解5例占16.7%,复发3例占10.0%。不良反应较轻。结论应用促性腺激素释放激素激动剂联合内美通治疗子宫内膜异位症,可以有效降低复发率,不良反应较轻,值得临床更进一步研究与实践应用。
Objective To explore the use of gonadotropin-releasing hormone agonist in combination with Nimethin in the treatment of endometriosis. The clinical efficacy and adverse drug reactions were analyzed. Methods Sixty patients with endometriosis were randomly divided into two groups: the treatment group (30 cases) and gonadotropin-releasing hormone agonist (25 cases), the control group (30 cases) received gonadotropin-releasing hormone Agent treatment. And the two groups of patients after treatment compared its efficacy and endocrine hormone E2 to understand the situation. Results After treatment of 60 patients with endometriosis, the treatment group: complete remission 26 cases accounted for 86.7%, partial remission in 2 cases accounted for 6.7%, recurrence in 2 cases accounted for 6.7%; control group: complete remission in 22 cases accounted for 73.3% 5 cases of partial remission accounted for 16.7%, 3 cases of recurrence accounted for 10.0%. Adverse reactions are mild. Conclusions The application of gonadotropin-releasing hormone agonist in combination with Nimesterone in the treatment of endometriosis can effectively reduce the recurrence rate with less adverse reactions and deserves further clinical research and practical application.